Backed by strong pre-clinical rationale, the combination of the anti-PDL1 antibody atezolizumab and the VEGF-neutralizing antibody bevacizumab has emerged as a first-line therapy for HCC. The gene discussed is VEGFA; the disease is hepatocellular carcinoma.